Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878272 | 1.00 | IDO1 (0.50) | IDO1HTR6CA1CA2PTPN7 | |
| SCHEMBL731798 | 0.89 | HTR6 (0.61) | IDO1HTR6CA1CA2 | |
| SCHEMBL11082095 | 0.84 | HTR6 (0.47) | IDO1HTR6CA1CA2HTT | |
| SCHEMBL9441442 | 0.82 | HTR6 (0.46) | IDO1HTR6CA1CA2HTT | |
| SCHEMBL1793811 | 0.82 | HTR6 (0.46) | IDO1HTR6CA1CA2HTT | |
| Methylamine SCHEMBL2996995 | 0.81 | HTR6 (0.47) | IDO1HTR6CA1CA2PTPN7 | |
| SCHEMBL3698920 | 0.81 | HTR6 (0.49) | IDO1HTR6CA1CA2PTPN7 | |
| SCHEMBL4885963 | 0.81 | HTR6 (0.49) | IDO1HTR6CA1CA2PTPN7 | |
| SCHEMBL3004774 | 0.81 | HTR6 (0.49) | IDO1HTR6CA1CA2PTPN7 | |
| SCHEMBL3004778 | 0.81 | HTR6 (0.49) | IDO1HTR6PTPN7HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522566-B2 | 2-(3-(2-methyl-6-(p-tolyl) pyridine-3-yl) ureido) benzenesulfonamide and derivatives as inhibitor of carbonic anhydrase IX for the treatment of cancer | YEDITEPE UNIVERSITESI (TR) | 2026-01-13 | — | — | US | disclosed |
| EP-3328833-B1 | SELECTIVE INHIBITORS OF CARBONIC ANHYDRASE | UNIV VILNIUS (LT) | 2025-08-06 | — | — | EP | disclosed |
| EP-4161910-B1 | 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER | UNIV YEDITEPE (TR) | 2025-01-08 | — | — | EP | disclosed |
| US-20230234926-A1 | 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER | YEDITEPE UNIVERSITESI (TR) | 2023-07-27 | — | — | US | disclosed |
| EP-4161910-A1 | 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER | Yeditepe Universitesi (TR) | 2023-04-12 | — | — | EP | disclosed |
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312682-B2 | Selective inhibitors of carbonic anhydrase | CA2, CA9, CA7 | IDO1 1146/4885HTR6 2999/4885CA1 6/4885 |
| US-20230234926-A1 | 2-(3-(2-METHYL-6-(P-TOLYL) PYRIDINE-3-YL) UREIDO) BENZENESULFONAMIDE AND DERIVATIVES AS INHIBITOR OF CARBONIC ANHYDRASE IX FOR THE TREATMENT OF CANCER | CA9, CA6, CA2 | IDO1 1600/4885HTR6 2240/4885CA1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.